1-Methylpiperazine → 5-(5-(7-(Trifluoromethyl)quinolin-4-yloxy)pentyloxy)-2-((4-methylpiperazin-1-yl)methyl)-4H-pyran-4-one

Methanesulfonic acid 4-oxo-5-[5-(7-trifluoromethyl-quinolin-4-yloxy)-pentyloxy]-4H-pyran-2-ylmethyl ester 17 (130 mg, 0.26 mmol) was dissolved in dichloromethane (5 mL). 1-Methyl-piperazine (75 μL, 0.67 mmol) was added via syringe. The mixture was stirred at 45° C. for 3 h. After cooling to room temperature CH2Cl2 (75 ml) was added and the mixture was washed with NaHCO3 10% (3×50 mL) and brine (3×50 mL). The organic layer was dried over MgSO4, filtered and evaporated. The crude product was purified by column chromatography on silica using as eluent CH2Cl2:MeOH=9:1. 5-(5-(7-(Trifluoromethyl)quinolin-4-yloxy)pentyloxy)-2-((4-methylpiperazin-1-yl)methyl)-4H-pyran-4-one EHT 0079 was obtained (30 mg, 23% yield) as a yellow oil.

1. additionwas added
2. washthe mixture was washed with NaHCO3 10% (3×50 mL) and brine (3×50 mL)
3. dry with materialThe organic layer was dried over MgSO4
4. filtrationfiltered
5. customevaporated
6. customThe crude product was purified by column chromatography on silica using as eluent CH2Cl2

ORD-Eintrag

ord-410be32db58a4eadb1781021808a1e92

Quelldatensatz

uspto-grants-2009_04

DOI

10.6084/m9.figshare.5104873.v1

Patentnummer

US07514432B2